CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia

American Journal of Cardiology

Volumn 93, Issue 1, 2004, Pages 104-107

  Kajinami, Kouji ^a   Brousseau, Margaret E ^b   Ordovas, Jose M ^b   Schaefer, Ernst J ^b  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A4; LOW DENSITY LIPOPROTEIN; MEVINOLIN;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0346433752     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2003.08.078     Document Type: Article

References (20)

1. Weinshilboum R. Inheritance and drug response. N Engl J Med. 348:2003;529-537.
2. Evans W.E., McLeod H. Pharmacogenomics. Drug disposition, drug targets, and side effects. N Engl J Med. 348:2003;538-549.
3. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 84:1999;413-428.
4. Bottorff M., Hansten P. Long-term safety of hepatic hydroxymethylglutaryl coenzyme A reductase inhibitors the role of metaboloism-monograph for physicians . Arch Intern Med. 160:2000;2273-2280.
5. Bolego C., Baetta R., Bellosta S., Corsini A., Paoletti R. Safety considerations for statins. Curr Opin Lipidol. 13:2002;637-644.
6. Davidson M., McKenney J., Stein E., Schrott H.G., Fayyad R., Black D. Comparison of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 79:1997;1475-1481.
7. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., Black D.M., Stein E.M., Corella D., Ordovas J.M. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 158:2001;183-193.
8. Cavalli S.A., Hirata M.H., Hirata R.D. Detection of MboII polymorphism at the 5′ promoter region of CYP3A4. Clin Chem. 47:2001;348-351.
9. Hamzeiy H., Vahdati-Mashhadian N., Edwards H.J., Goldfarb P.S. Mutation analysis of the human CYP3A4 gene 5′ regulatory region population screening using non-radioactive SSCP . Mutat Res. 500:2002;103-110.
10. Nelson D.R., Kamataki T., Waxman D.J., Guengerich F.P., Estabrook R.W., Feyereisen T., Waxman D.J., Guengerich F.P., Estabrook R.W., Feyereisen R., et al. The P450 superfamily update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature . DNA Cell Biol. 12:1993;1-51.
11. Kantola T., Krivisto K.T., Neuvonen P.J. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharamacol Ther. 64:1998;58-65.
12. Siedlik P.H., Olson S.C., Yang B.B. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 39:1999;501-504.
13. Nordin C., Dahl M.L., Eriksson M., Sjoberg S. Is the cholesterol- lowering effect of simvastatin influenced by CYP2D6 polymorphism? Lancet. 350:1997;29-30.
14. Mulder A.B., van Lijf H.J., Bon M.A., van den Bergh F.A., Touw D.J., Neef C., Vermes I. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther. 70:2001;546-551.
15. Rebbeck T.R., Jaffe J.M., Walker A.H., Wein A.J., Malkowicz S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 90:1998;1225-1229.
16. Felix C.A., Walker A.H., Lange B.J., Williams T.M., Winick N.J., Cheung N.K., Lovett B.D., Nowell P.C., Blair I.A., Rebbeck T.R. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA. 95:1998;13176-13181.
17. Ando Y., Tateishi T., Sekido Y., Yamamoto T., Satoh T., Hasegawa Y., Kobayashi S., Katsunuma T., Shimokata K., Saito H. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 91:1999;1587-1590.
18. Rebbeck T.R. More about modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 . (letter) J Natl Cancer Inst. 92:2000;76.
19. Amirimani B., Walker A.H., Weber B.L., Rebbeck T.R. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 91:1999;1588-1590.
20. Sata F., Sapone A., Elizondo G., Stocker P., Miller V.P., Zheng W., Hannu R., Charles L.C., Gonzalez F.J. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12 evidence for an allelic variant with altered catalytic activity . Clin Pharmacol Ther. 67:2000;48-56.